Edwin De Graaf
managing partner
Medicine
AM-Pharma
Netherlands
Biography
Edwin de Graaf is a managing partner of Gilde Healthcare. He led Gilde’s investments in GlycArt (trade sale to Roche), IDEA (license to Alpharma Pharmaceuticals), Omegatech (trade sale to Martek Biosciences, now DSM), Pieris, Prosonix, Santaris Pharma (trade sale to Roche) and uniQure (IPO on NASDAQ). Edwin represented Gilde on the boards of Glycart, IDEA, Santaris Pharma and uniQure and currently serves on the boards of AM Pharma, Ascendis Pharma, Pieris and Prosonix. Edwin joined Gilde as an investment manager of Gilde Strategic Situations -a fund of funds- where he was involved in investments in funds in Europe and the United States in 1997. Two years later, he joined Gilde’s health care fund. Prior to Gilde, Edwin was a tax consultant with Coopers & Lybrand (now PwC) for three years.
Research Interest
Pharmaceutical
